Cipla block deal: 1.72% equity changes hands; promoter likely seller

The offer price, as per reports, was set at ₹1,442 per share, showing a 6% discount to the last traded price. The report added that the total size of the transaction was estimated to be around ₹2,000 crore.

Cipla Q2 FY25 Results

The company had reported a net profit of ₹1,115 crore in the July-September quarter of the last fiscal year.

Its total income from operations rose to ₹7,051 crore in the second quarter compared to ₹6,490 crore in the year-ago period, Cipla said in a regulatory filing.

"In Q2 FY25, we recorded a revenue growth of 9% over the last year with the highest-ever EBITDA margin of 26.7%, driven by mix and other operational efficiencies," Cipla MD and Global CEO Umang Vohra said.

The company's 'One-India' business was impacted during the quarter due to a changed seasonal pattern. However, key chronic therapies in the branded prescription business continued to grow faster than the market, the CEO added.

The company's consumer health business grew at a strong 21% year-on-year, Vohra said.

"With our concentrated focus on the differentiated portfolio, the US business posted a revenue of $237 million. In South Africa, we recorded solid growth of 22% y-o-y in local currency terms, led by the private market," Vohra said further.

Emerging Markets and Europe delivered a robust revenue growth of 18% on the back of a deep market focus strategy, Vohra said.